Clinical trial to assess if mangosteen extract can help treat schizophrenia

By Gary Scattergood contact

- Last updated on GMT

"We aren’t suggesting this is a wonder drug, but we must investigate," says Professor John McGrath.
"We aren’t suggesting this is a wonder drug, but we must investigate," says Professor John McGrath.

Related tags: Clinical trial

Researchers have begun clinical trials to assess if an extract from mangosteen can help treat schizophrenia.

Mangosteen is a tropical evergreen fruit native to Indonesia. The thick purple rind of the fruit contains xanthones, which are often used in herbal teas and traditional medicines.

Queensland Brain Institute​ Professor John McGrath​ is now conducting a trial into the role of mangosteens in easing symptoms of psychosis.

Previous research has indicated that the very potent antioxidants in mangosteen rind might provide a safe and effective treatment, with no side-effects.

“This is a gentle and safe intervention which evidence so far suggests could improve symptoms, and it’s important we investigate its potential as a matter of urgency,” ​Professor McGrath said.

“We aren’t suggesting this is a wonder drug, but we must investigate potential new treatments which are safe, effective and don’t have the current medication’s side-effects like weight gain, which can lead to other major health problems.

“Finding better treatments for schizophrenia is difficult, it will take decades, so let’s start now.”

Citizen scientists

For this trial run through Cadence​, 150 people with schizophrenia will be recruited over the next two years in Brisbane and in Geelong, Victoria with colleagues at Deakin University.

Participants will receive two tablets a day for 24 weeks, then have four weeks’ follow-up. Their symptoms will be closely monitored, to see whether hallucinations, delusions, moods and energy levels are improved.

“When people join a clinical trial like this, they become our citizen scientists, part of our research team.

“That is an inspiring and heart-warming trust which we hope will ultimately lead to better lives for all patients, even if it’s only a modest improvement,”​ Professor McGrath said.

The Cadence trials are funded by Professor McGrath’s National Health and Medical Research Council John Cade Fellowship in Mental Health Research, and by a grant from the Stanley Medical Research Institute​ in the US.

Related topics: Research, Cognitive function

Related news

Show more

Related products

DurOmega® Algal DHA 20% water dispersible powder

DurOmega® Algal DHA 20% water dispersible powder

INNOBIO Corporation Limited | 30-May-2022 | Technical / White Paper

INNOBIO most recently launched a new product DurOmega® Algal DHA 20% water dispersible powder with significantly reduced fishy odor and taste, which optimizes...

Total Solutions for Cognitive Health by Lubrizol

Total Solutions for Cognitive Health by Lubrizol

Lipofoods, a Lubrizol Company | 05-May-2022 | Technical / White Paper

Globally, health and wellbeing have shifted from a focus on physical health and nutrition to also include cognitive and mental wellness, therefore consumers...

A premium grade of spirulina

A premium grade of spirulina

Robertet Health & Beauty | 20-Mar-2022 | Technical / White Paper

Robertet and fleur-2-vie joined their expertise to unveil Spiruline Safe®, a premium quality of Spirulina produced through a unique, fully controlled process...

Total Solutions for Cognitive Health by Lubrizol

Total Solutions for Cognitive Health by Lubrizol

Lipofoods, a Lubrizol Company | 02-Mar-2022 | Product Presentation

Globally, health and wellbeing have shifted from a focus on physical health and nutrition to also include cognitive and mental wellness, therefore consumers...

Related suppliers

Follow us

Products

View more

Webinars